EQT

A consortium led by financial investor EQT is offering €46.50 per share (about €10.8 billion including debt) for diagnostics specialist Qiagen and intends to take the company private. The deal, internally dubbed “Project Crown”, would be the largest private-equity takeover of a listed German company and the second-largest PE transaction in Germany overall. EQT cites planned investments in innovation, the product portfolio and sales; closing is expected in mid-2027, and the transaction uses Dutch law for the delisting. Qiagen’s supervisory board and management board support the offer; advisors involved include Morgan Stanley, Jefferies, Goldman Sachs and Linklaters. » More on faz.net

Private equity firm EQT has agreed a cash offer for Qiagen that values the company at about €10.8 billion and provides €46.50 per share. The takeover vehicle is to include, among others, the Abu Dhabi sovereign wealth fund and CPP Investment Board; completion is expected in mid‑2027 and is subject to regulatory approvals and a minimum acceptance threshold of 50 percent plus one share. Qiagen’s management board and supervisory board support the offer and recommend acceptance; if the threshold is met, EQT plans a squeeze‑out and the delisting of the stock in Frankfurt and New York. » More on finanzen.net

The financial investor EQT intends to acquire Qiagen and, together with a consortium reportedly including a sovereign wealth fund from Abu Dhabi and the Canadian pension fund CPP, is offering €46.50 per share in cash. The offer includes a minimum acceptance threshold of 50 percent plus one share and values Qiagen at an enterprise value including debt of about €10.8 billion. Qiagen released preliminary figures for the third quarter, suspended its 2026 guidance because of the takeover offer, and the stock showed slight movements in Europe and a gain in the US. » More on finanzen.net